ImportantUpdates

Company's Board approved solid Q4/FY financial results: ₹107.66 Cr revenue & ₹13.11 Cr profit.

Par Drugs and Chemicals Limited logo
Par Drugs and Chemicals LimitedPAR · Filed with the exchange

Strong operating cash flow at ₹16.43 Cr.

Greenlit ₹90 Cr for liquid fund investments and renewed a ₹1.61 Cr banking facility.

Strategic restructuring faces regulatory delays, yet auditors affirm going concern.

Read the original filing(PDF)

No comments yet. Be the first.

More from Par Drugs and Chemicals Limited

All announcements